236 related articles for article (PubMed ID: 20517659)
1. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.
Peng A; Straubinger RM; Balu-Iyer SV
AAPS J; 2010 Sep; 12(3):473-81. PubMed ID: 20517659
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.
Kosloski MP; Pisal DS; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2014 Apr; 35(3):154-63. PubMed ID: 24259187
[TBL] [Abstract][Full Text] [Related]
3. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.
Peng A; Kosloski MP; Nakamura G; Ding H; Balu-Iyer SV
AAPS J; 2012 Mar; 14(1):35-42. PubMed ID: 22173945
[TBL] [Abstract][Full Text] [Related]
4. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
Purohit VS; Ramani K; Sarkar R; Kazazian HH; Balasubramanian SV
J Biol Chem; 2005 May; 280(18):17593-600. PubMed ID: 15728582
[TBL] [Abstract][Full Text] [Related]
5. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
6. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.
Miclea RD; Purohit VS; Balu-Iyer SV
AAPS J; 2007 Jun; 9(2):E251-9. PubMed ID: 17907766
[TBL] [Abstract][Full Text] [Related]
7. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
[TBL] [Abstract][Full Text] [Related]
8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
9. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of lipidic cochleate containing recombinant factor VIII.
Miclea RD; Varma PR; Peng A; Balu-Iyer SV
Biochim Biophys Acta; 2007 Nov; 1768(11):2890-8. PubMed ID: 17936245
[TBL] [Abstract][Full Text] [Related]
11. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.
Ramani K; Miclea RD; Purohit VS; Mager DE; Straubinger RM; Balu-Iyer SV
J Pharm Sci; 2008 Apr; 97(4):1386-98. PubMed ID: 17705286
[TBL] [Abstract][Full Text] [Related]
13. Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.
Shetty KA; Merricks EP; Raymer R; Rigsbee N; Nichols TC; Balu-Iyer SV
J Pharm Sci; 2016 Aug; 105(8):2459-64. PubMed ID: 27372547
[TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.
Gaitonde P; Purohit VS; Balu-Iyer SV
Eur J Pharm Sci; 2015 Jan; 66():157-62. PubMed ID: 25459532
[TBL] [Abstract][Full Text] [Related]
15. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.
Pratt KP; Qian J; Ellaban E; Okita DK; Diethelm-Okita BM; Conti-Fine B; Scott DW
Thromb Haemost; 2004 Sep; 92(3):522-8. PubMed ID: 15351848
[TBL] [Abstract][Full Text] [Related]
16. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
[TBL] [Abstract][Full Text] [Related]
17. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice.
Peng A; Gaitonde P; Kosloski MP; Miclea RD; Varma P; Balu-Iyer SV
J Pharm Sci; 2009 Dec; 98(12):4480-4. PubMed ID: 19499565
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice.
Bloem E; Karpf DM; Nørby PL; Johansen PB; Loftager M; Rahbek-Nielsen H; Petersen HH; Blouse GE; Thim L; Kjalke M; Bolt G
J Thromb Haemost; 2019 Feb; 17(2):350-360. PubMed ID: 30525289
[TBL] [Abstract][Full Text] [Related]
19. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
20. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
